Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102112 | 0.84 | SCN3A (0.56) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1606434 | 0.76 | SMN1; SMN2 (0.60) | MAPTTP53SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1102092 | 0.74 | ALDH1A1 (0.55) | MAPTSMN1; SMN2MEN1KMT2ARXFP1 | |
| SCHEMBL1105771 | 0.73 | ALDH1A1 (0.46) | MAPTSMN1; SMN2MEN1KMT2ARXFP1 | |
| SCHEMBL9974118 | 0.71 | SCN3A (0.60) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL9974134 | 0.69 | SCN3A (0.57) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL8388544 | 0.69 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL31346924 | 0.69 | MEN1 (0.77) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31346908 | 0.69 | GAA (0.79) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL13212143 | 0.68 | RAB9A (0.65) | MAPTTP53SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | MAPT 1883/4885TP53 4752/4885SMN1; SMN2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.